Taiwan Industry Reports
Industry Type:   Title:  

 
2023 Western Medicine and biopharmaceutical
2022-NovDoc #37097Annual Report (condensed version)US$150
With its enormous biomedicine and information and communication resources, Taiwan is set to become a key partner of major foreign biopharmaceutical companies.
Agricultural Biotechnology
2022-OctDoc #37134Industry Report (condensed version)US$100
The production and sales of biopesticides and biofertilizers at home and abroad will rise because of the global impetus on green agriculture, circular economy and ecological protection. Consequently, the agricultural biotechnology industry will witness a stable growth in 2023.
Raw Material Medicine Manufacturing
2022-JulDoc #36540Industry Report (condensed version)US$100
Demand in the end market remains strong, suggesting active pharmaceutical ingredient firms with niche products will benefit from the restructuring process of the pharmaceutical supply chains in Europe and the United States and generic drug companies in Taiwan. Consequently, the industry climate will be slightly favorable in the second half of 2022.
Food Biotechnology Industry
2022-JunDoc #36389Industry Report (condensed version)US$100
COVID-19 may transition to an ordinary seasonal virus in the second half of 2022. Meanwhile, the costs of some materials continue to rise, and there is little room for an improvement in transport capacity worldwide, subduing the industry’s gross margin.
Specialized Biotechnology Industry
2022-MayDoc #36242Industry Report (condensed version)US$100
Efforts to integrate physical stores and e-commerce platforms bear fruit. The move helps the firms explore overseas markets such as the Association of South-East Asian Nations, suggesting sales of some domestic medicated cosmetics will maintain growth.
Raw Material Medicine Manufacturing
2022-JanDoc #35700Industry Report (condensed version)US$100
The industry is expected to return to growth track in the first half of 2022 as efforts to explore new markets overseas begin to bear fruit and firms gradually resume production capacity.
2022 Western Medicines and Biopharmaceuticals
2021-DecDoc #35332Annual Report (condensed version)US$100
The coronavirus pandemic will turn into a seasonal influenza, auguring well for Taiwan’s exports sales of western medicines, raw materials and biological medicines.
Regenerative Medicine
2021-NovDoc #35478Industry Report (condensed version)US$75
Given the government’s commitment to new policies, the existing cell storage business will continue to grow steadily, accelerate clinical progress in the cell therapy program, and strengthen the competitiveness of Taiwan’s contract manufacturing organizations. As a result, the industry climate is expected to be favorable in 2022.
Food Biotechnology Industry
2021-OctDoc #35231Industry Report (condensed version)US$75
Taiwanese firms continue to explore emerging markets, and their efforts to develop the China market is expected to bear fruit. Given a positive outlook for sales at home and abroad, the industry climate will be favorable in the first half of 2022.
Raw Material Medicine Manufacturing
2021-SepDoc #35098Industry Report (condensed version)US$75
Most of the countries in emerging markets will continue to grapple with the coronavirus pandemic in the second half of 2021, spurring demand for active pharmaceutical ingredients for antibiotics and anticoagulants.
 First  Previous  Next  Last  In  1  /  6  Page  (Find  56  records)
 





Copyright (c) 2018 All Rights Reserved by
Taiwan Institute of Economic Research
Taiwan Industry Economics Services
Address: 4Fl., 16-8, Tehui St., Taipei, Taiwan
TEL: 886-2-25865000 ext469; FAX: 886-2-25935543